Skip to content

US · AKTX · BIOTECHNOLOGY

Akari Therapeutics, Plc (AKTX) intrinsic value and stock valuation

$7.18as of 2026-11-21 · Mkt cap 8.58M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Akari Therapeutics, Plc DCF and intrinsic value

InvestorsCraft values AKTX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AKTX’s statements →

Akari Therapeutics, Plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Tampa, FL 33602 akaritx.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-17.3M
20112025
Free cash flow
-$-10.57M
20112025
Total equity
$28.3M+24.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-17.27M-$-21.64M-$-16.81M-$-23.09M-$-17.21M
Net income-$-17.3M-$-19.79M-$-10.01M-$-17.75M-$-17.42M
EPSd-$-865M-$-1.98B———
Operating cash flow-$-10.57M-$-12.55M-$-16.43M-$-21.5M-$-18.85M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-10.57M-$-12.55M-$-16.43M-$-21.5M-$-18.85M
Total assets$47.9M$50.6M$4.36M$13.8M$11.7M
Total debt$750K$3.26M$0.00$0.00$0.00
Net debt-$-4.45M$660K-$-3.85M-$-13.25M-$-9.36M
Total equity$28.3M$22.2M-$-230K$1.79M$5.55M
Cash and short-term investments$5.2M$2.6M$3.85M$13.3M$9.36M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$2.81M$6.98M$8.02M$9.56M$9.13M
Selling, general and administrative expenses$9.28M$9.66M$11.4M$13.5M$8.08M
Other expenses$5.18M$5M-$-2.57M$0.00$0.00
Operating expenses$17.3M$21.6M$16.8M$23.1M$17.2M
Cost and expenses$17.3M$21.6M$16.8M$23.1M$17.2M
Interest income$0.00$10K$80K$50K$10K
Interest expense$950K-$-240K$0.00$0.00$0.00
Depreciation and amortization$0.00$10K$0.00$0.00$0.00
Ebitda-$-17.35M-$-19.53M-$-10M-$-17.74M-$-17.42M
Operating income-$-17.27M-$-21.64M-$-16.81M-$-23.09M-$-17.21M
Total other income/expenses, net-$-1.03M$1.85M$6.8M$5.34M-$-210K
Income before tax-$-18.3M-$-19.79M-$-10.01M-$-17.75M-$-17.42M
Income tax expense-$-1M$0.00$0.00$0.00$0.00
Net income-$-17.3M-$-19.79M-$-10.01M-$-17.75M-$-17.42M
Weighted average shares outstanding$20K$10K$0.00$0.00$0.00
Weighted average diluted shares outstanding$20K$10K$0.00$0.00$0.00
Balance sheet
20252024202320222021
Cash and short-term investments$5.2M$2.6M$3.85M$13.3M$9.36M
Net receivables$0.00$200K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$5.46M$2.95M$4.34M$13.8M$11.6M
Property, plant and equipment, net$0.00$0.00$0.00$0.00$0.00
Goodwill and intangible assets$42.4M$47.6M$10K$20K$20K
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$42.4M$47.6M$10K$20K$20K
Total assets$47.9M$50.6M$4.36M$13.8M$11.7M
Accounts payable$8.77M$12.4M$1.67M$950K$1.79M
Short-term debt$750K$3.26M$0.00$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$12.4M$19.9M$4.58M$12M$6.09M
Long-term debt$0.00$0.00$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$7.21M$8.42M$0.00$0.00$0.00
Capital lease obligations$0.00$0.00$0.00$0.00$0.00
Total liabilities$19.6M$28.3M$4.58M$12M$6.09M
Common stock$0.00$5.32M$1.32M$740K$480K
Retained earnings-$-264.55M-$-247.25M-$-227.46M-$-217.45M-$-199.71M
Accumulated other comprehensive income (loss)-$-780K-$-740K$51.2M$51.4M$51.7M
Total equity$28.3M$22.2M-$-230K$1.79M$5.55M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$750K$3.26M$0.00$0.00$0.00
Net debt-$-4.45M$660K-$-3.85M-$-13.25M-$-9.36M
Cash flow statement
20252024202320222021
Net income-$-17.3M-$-19.79M-$-10.01M-$-17.75M-$-17.42M
Depreciation and amortization$0.00$10K$0.00$0.00$0.00
Stock-based compensation$2.89M$2.25M$1.15M$730K$310K
Change in working capital-$-400K$6.54M-$-870K$820K-$-1.98M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00-$-240K
Net cash provided by operating activities-$-10.57M-$-12.55M-$-16.43M-$-21.5M-$-18.85M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$380K$0.00$0.00$0.00
Net cash used for investing activities$0.00$380K$0.00$0.00$0.00
Common stock issued$12.1M$11.8M$7.02M$25.2M$14.3M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$13.2M$11M$7.02M$25.3M$14.3M
Net change in cash$2.6M-$-1.19M-$-9.4M$3.89M-$-4.69M
Cash at end of period$5.26M$2.66M$3.85M$13.3M$9.36M
Operating cash flow-$-10.57M-$-12.55M-$-16.43M-$-21.5M-$-18.85M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-10.57M-$-12.55M-$-16.43M-$-21.5M-$-18.85M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Akari Therapeutics, Plc

        Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.

        CEO
        Abizer Gaslightwala
        Employees
        6
        Beta
        1.39

        Explore

        Frequently asked questions

        What is the intrinsic value of Akari Therapeutics, Plc (AKTX)?

        InvestorsCraft does not currently publish an intrinsic value for AKTX. How the IC value is calculated.

        Is AKTX undervalued?

        InvestorsCraft does not publish an undervaluation signal for AKTX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.